Oramed Pharmaceuticals (ORMP) Receivables (2011 - 2015)

Oramed Pharmaceuticals' (ORMP) quarterly Receivables came in at $33000.0 in Q2 2015, down 91.91% on a QoQ basis from $408000.0 in Q3 2014.

Oramed Pharmaceuticals (ORMP) Receivables (2011 - 2015) Analysis & Trends

Oramed Pharmaceuticals (ORMP) has 5 years of Receivables data on file, last reported at $33000.0 in Q2 2015.

Quarterly Receivables changed N/A year-over-year to $33000.0 in Q2 2015, while the trailing twelve-month figure through May 2015 was $33000.0 (changed N/A YoY) and the FY2014 annual result came in at $408000.0, changed N/A from the prior year.
Receivables slipped to $33000.0 in Q2 2015, from $408000.0 in the prior quarter.
In the past five years, Receivables ranged from a high of $567082.0 in Q3 2011 to a low of $33000.0 in Q2 2015.
A 5-year average of $289490.2 and a median of $219004.0 in 2012 frame the typical range for Receivables.
Annual changes were most pronounced in 2012 — Receivables sank 69.61% — and 2013, when it surged 621.81%.
Tracing ORMP's Receivables over 5 years: stood at $149961.0 in 2011, then advanced by 17.02% to $175483.0 in 2012, then surged by 192.06% to $512519.0 in 2013, then fell by 20.39% to $408000.0 in 2014, then tumbled by 91.91% to $33000.0 in 2015.
The last three Receivables figures came in at $33000.0 (Q2 2015), $408000.0 (Q3 2014), and $512519.0 (Q2 2013), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	1.93 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	912.74 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	1.09 Bn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	215.33 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Oramed Pharmaceuticals	197.61 Mn	197.61 Mn	-	-

Download Data